-
1.发明公开公开(公告)号：US20240316056A1
公开(公告)日：2024-09-26
申请号：US18735506
申请日：2024-06-06
申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services , University of Kansas , Northwestern University
发明人： Udo Rudloff , Serguei Kozlov , Juan Jose Marugan , Sui Huang , Samarjit Patnaik , John C. Braisted , Noel T. Southall , Marc Ferrer , Christopher Dextras , John Haslam , Michael Baltezor
IPC分类号： A61K31/519 , A61K31/7068 , A61K45/06 , A61K47/12 , A61P35/04
CPC分类号： A61K31/519 , A61K31/7068 , A61K45/06 , A61K47/12 , A61P35/04
摘要： Disclosed are pharmaceutical formulations comprising a compound of formula (I):
in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US11634404B2
公开(公告)日：2023-04-25
申请号：US16093365
申请日：2017-04-14
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services , The University of Kansas , The University of North Carolina at Chapel Hill
发明人： David R. Sibley , Amy Elizabeth Moritz , R. Benjamin Free , Joseph P. Steiner , Noel Terrence Southall , Marc Ferrer , Xin Hu , Warren S. Weiner , Jeffrey Aubé , Kevin Frankowski
IPC分类号： C07D401/12 , A61P25/28 , C07D295/185 , C07D209/42 , C07D213/65 , C07D213/81 , C07D235/24 , C07D307/85 , C07D317/64 , C07D333/70 , C07D405/12 , C07D409/12 , C07D471/04
摘要： The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.
-
公开(公告)号：US11241436B2
公开(公告)日：2022-02-08
申请号：US16480885
申请日：2018-01-25
申请人： Northwestern University , The United States of America,as represented by the Secretary,Department of Health and Human Services , University of Kansas
发明人： Congcong He , Sui Huang , Chen Wang , Altea Rocchi , Juan Jose Marugan , Marc Ferrer , Samarjit Patnaik , Yuchi Chen , Kevin Frankowski , Frank J. Schoenen
IPC分类号： A61K31/519 , A61P25/30 , A61K31/704
摘要： The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.
-
公开(公告)号：US10202367B2
公开(公告)日：2019-02-12
申请号：US15317864
申请日：2015-06-12
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services , University of Kansas
发明人： Tsanyang Liang , Zongyi Hu , Juan Jose Marugan , Noel Terrence Southall , Shanshan He , Xin Hu , Jingbo Xiao , Marc Ferrer , Wei Zheng , Kevin J. Frankowski , Frank J. Schoenen , Kelin Li
IPC分类号： C07D413/14 , A61K31/4545 , C07D417/14 , C07D471/08 , A61K31/496 , A61K31/5377 , C07D413/06 , A61K31/4178 , A61K31/454 , A61K31/7056 , A61K31/7068 , A61K38/07 , A61K38/13 , A61K38/21
摘要： Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.
-
公开(公告)号：US11471460B2
公开(公告)日：2022-10-18
申请号：US16883046
申请日：2020-05-26
申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services
IPC分类号： A61K31/53 , A61P35/00 , A61K31/506 , C07D239/50 , C07D251/54 , C07D403/12
摘要： Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: wherein R1, R2, and R3 are as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.
-
公开(公告)号：US20200369649A1
公开(公告)日：2020-11-26
申请号：US16883046
申请日：2020-05-26
申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services
IPC分类号： C07D403/12 , C07D251/54 , C07D239/50 , A61P35/00
摘要： Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: wherein R1, R2, and R3 are as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.
-
公开(公告)号：US11766423B2
公开(公告)日：2023-09-26
申请号：US16977305
申请日：2019-03-01
申请人： THE JOHNS HOPKINS UNIVERSITY , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH
发明人： Barbara Slusher , Camilo Rojas , Ajit G. Thomas , Norman Haughey , Marc Ferrer , Xin Hu
IPC分类号： A61K31/4178 , A61P25/28
CPC分类号： A61K31/4178 , A61P25/28
摘要： Methods for treating one or more diseases associated with neutral sphingomyelinase 2 (nSMase2) in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of 2,6-dimethoxy-4-(5-phenyl-4-thiophen-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) or a pharmaceutically acceptable salt thereof, are disclosed.
-
公开(公告)号：US11253511B2
公开(公告)日：2022-02-22
申请号：US16068208
申请日：2017-01-04
申请人： THE JOHNS HOPKINS UNIVERSITY , THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
发明人： Ravit Boger , Marc Ferrer , Juan Marugan , Andres Dulcey Garcia , Noel Terrence Southall , Xin Hu
IPC分类号： A61K31/4745 , A61K31/522 , A61P31/22 , A61K38/05 , A61P31/20 , A61K45/06 , A61K9/00
摘要： The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.
-
公开(公告)号：US20230312511A1
公开(公告)日：2023-10-05
申请号：US18111241
申请日：2023-02-17
申请人： The United States of America, as represented by the Secretary, Department of Health and Human , The University of Kansas , The University of North Carolina at Chapel Hill
发明人： David R. Sibley , Amy Elizabeth Moritz , R. Benjamin Free , Joseph P. Steiner , Noel Terrence Southall , Marc Ferrer , Xin Hu , Warren S. Weiner , Jeffrey Aubé , Kevin Frankowski
IPC分类号： C07D401/12 , A61P25/28 , C07D209/42 , C07D213/65 , C07D213/81 , C07D235/24 , C07D295/185 , C07D307/85 , C07D317/64 , C07D333/70 , C07D405/12 , C07D409/12 , C07D471/04
CPC分类号： C07D401/12 , A61P25/28 , C07D209/42 , C07D213/65 , C07D213/81 , C07D235/24 , C07D295/185 , C07D307/85 , C07D317/64 , C07D333/70 , C07D405/12 , C07D409/12 , C07D471/04
摘要： The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof
The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.-
公开(公告)号：US20210040074A1
公开(公告)日：2021-02-11
申请号：US16977897
申请日：2019-03-06
申请人： David R. Sibley , Kathryn D. Luderman , Jennie L. Conroy , R. Benjamin Free , Prashi Jain , Noel T. Southall , Marc Ferrer , Jeffrey Aubé , Kevin Frankowski , The United States of America,as represented by the Secretary,Department of Health and Human Service , University of Kansas , The University of North Carolina at Chapel Hill
发明人： David R. Sibley , Kathryn D. Luderman , Jennie L. Conroy , R. Benjamin Free , Prashi Jain , Noel T. Southall , Marc Ferrer , Jeffrey Aubé , Kevin Frankowski
IPC分类号： C07D409/12 , C07D471/04
摘要： Disclosed are compounds of formulas (I) and (III) for treating or preventing a disease or disorder responsive to activation of a D1 dopamine receptor agonist in a mammal in need thereof, wherein m, n, R1-R6, and R11-R13 are as defined herein. Examples of such disease or disorder include Alzheimer's Disease, schizophrenia, Parkinson's disease, a dyskinesia, and Huntington's disease.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.032 秒)
